How can surgical robotics manufacturers deliver targeted innovations that dramatically improve patient outcomes and cost-efficiency in healthcare? It’s about developing procedural solutions that clearly surpass what humans can achieve. Clinical and financial benefits need to be tangible and measurable, so end-users can build a robust business case for investment. By Rob Morgan, VP Medical, Sagentia.Subscribe now to read the full analysis
Welcome to MyStrategist, an online experience like no other in the medical device industry.
With MyStrategist, quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and MedTech Strategist Market Pathways – now on an all-in-one, digital platform. We invite you to explore our coverage.
Think Strategically. Subscribe Today.
Registration is now open for the 7th annual Innovation Summit Dublin, April 21-23, 2020. The industry's most anticipated event will sell out. Register Today.Register Learn More
The number of warning letters sent to device companies by FDA have nose-dived, but citations addressing lapses in pre-market approvals or clearances for marketed products remained relatively robust last year. Here’s a look at some key 2019 warning letter trends.Subscribe now to read the full analysis
Our strategic publications provide actionable intelligence to support each member of your organization. Check to see if your company has access.Learn More
At long last, the device tax is heading for permanent repeal in a year-end spending bill that is expected to be enacted this week.Subscribe now to read the full analysis